Global Glycobiology Market to Surpass US$ 2,700.5 Million by 2027, Says Coherent Market Insights (CMI)

According to Coherent Market Insights, the global glycobiology market is estimated to be valued at US$ 1,165.3 million in 2020 and is expected to exhibit a CAGR of 12.8% during the forecast period (2020-2027).

Key Trends and Analysis of the Global Glycobiology Market:

Key trends in the global glycobiology market include increase in product launches by key companies, which is expected to drive the global glycobiology market growth over the forecast period. For instance, In March 2017, Bruker Corporation announced the launch of its new nuclear magnetic spectroscopy instrument - AVANCE NEO. The new AVANCE NEO has advanced AVANCE III HD by offering even faster control, improved dynamic range, and enhanced flexibility and scalability.

Furthermore, key players operating in the global glycobiology market are focusing on adoption of inorganic growth strategies to increase their market presence in the global market. For instance, in May 2020, Thermo Fisher Scientific Inc., collaborated with Biognosys, a leading developer of next-generation proteomics solutions. The collaboration focused on data independent acquisition mass spectrometry (DIA-MS) based workflows and in developing a quantified workflow for accurate and flexible label-free protein quantitation and proteome profiling in plasma matrices.

Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/3639

Key Market Takeaways:

The global glycobiology market is expected to exhibit a CAGR of 12.8% during the forecast period due to key players in the market are focusing on adopting growth strategies such as expansion in order to strengthen its position in market which is expected to boost the global glycobiology market over the forecast period. For instance, In December 2020, Merck & Co., Inc. announced the expansion of its life sciences (biopharmaceutical product manufacturing, industrial microbiology products, materials and regents) production capacity in the U.S. by investing US$ 48.53 million in their production facilities in Danvers, Massachusetts, and Jaffrey, New Hampshire, U.S.

Among product type, Enzymes segment is estimated to hold a dominant position in the global glycobiology market over the forecast period. Moreover, increasing collaborations between key players for research and developments in glycoproteins and Glycans is expected to drive the segment growth. For instance in November 2019, MOBILion Systems, Inc. collaborated with researchers at the University of Georgia, for R&D in Glycans and glycoprotein

In terms of end user, Pharmaceutical Companies segment is estimated to hold dominant position in the global glycobiology market over the forecast period. Pharmaceutical companies operating in the glycobiology market are focusing on research and development of roles of carbohydrates including mediating adhesion of pathogens and toxins to host cells, the appearance of tumor-associated antigens, the regulation of blood coagulation, and the circulatory half-life of plasma glycoproteins for immune system. Thus, increasing research and development activities carried out by pharmaceutical companies is expected to drive the segment growth over the forecast period.

Competitive Landscape:

Key players operating in the global glycobiology market are Bio-Techne Corporation, Bruker Corporation, Thermo Fisher Scientific Inc., Shimadzu Corporation, Plexera LLC, New England Biolabs, and Agilent Technologies, Inc.

Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/3639

Market Segmentation:

• Glycobiology Market, By Product Type:
  • Instruments
  • Enzymes
    • Galactosidases
      • Fucosidases
      • Chitinases
      • Acetylgalactosaminidase
      • Heparinase
      • PNGase F
      • Others
    • GlcNAc Transferases
      • Acetylglucosaminyltransferase
      • Exostosin
      • Others
      • Fucosyltransferases
      • GalNAc Transferases
      • Galactosyl Transferases
      • Glucuronosyltransferases
      • Glucosyltransferases
      • Pentosyltransferases
      • Carbohydrate Kinases
      • Neuraminidases
      • Sialyltransferases
      • Others
  • Consumables
  • Reagents & Kits
• Glycobiology Market, By Application:
  • Drug Discovery and Development
  • Diagnostic Applications
    • Oncology
    • Immunology
    • Others
  • Industrial Application
  • Therapeutic Application
    • Oncology
    • Immunology
    • Others
  • Others
• Glycobiology Market, By End User:
  • Pharmaceutical Companies
  • Research Laboratories
  • Hospitals
  • Diagnostic Centers
  • Contract Research Organizations
  • Biotechnology Companies
  • Academic Institutes
  • Others
• Glycobiology Market, By Region:
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Central Africa
    • North Africa

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. Our client base includes players from across various business verticals in over 57 countries worldwide.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210521005163/en/

Global Glycobiology Market is expected to grow at a CAGR of 12.8% during the forecast 20202-2027, Says Coherent Market Insights